Printer Friendly

Global Sleep Aids Market to Reach USD 79.85bn by 2022, Research and Markets Forecasts.

M2 PHARMA-May 8, 2017-Global Sleep Aids Market to Reach USD 79.85bn by 2022, Research and Markets Forecasts

(C)2017 M2 COMMUNICATIONS

- The global sleep aids market was valued at USD 49.543bn in 2016, and is estimated to reach USD 79.851bn by 2022, registering a CAGR of 7.0% from 2017 to 2023, according to a new report from Dublin-based Research and Markets.

Sleep aids are drugs and devices that are used to diagnose and treat sleep disorders, such as sleep apnea and insomnia.

Sleep disorders are caused due to substance misuse, stressful work environment, and inconsistent sleep pattern.

Sleep aids help to improve the quality of sleep by reducing the time required to fall asleep and increasing the duration of quality sleep.

The global sleep aids market is segmented based on product, sleep disorder, and geography. Based on product, it is categorised into mattress and pillows, sleep laboratories, medications, and sleep apnea devices.

The medications segment is further divided into prescription-based drugs, over-the-counter drugs, and herbal drugs.

Based on sleep disorder, it is classified into insomnia, sleep apnea, restless leg syndrome, narcolepsy, sleep walking, and other sleep disorder.

The market growth is attributed to the surge in prevalence of sleep disorders, rise in geriatric and obese population, and change in lifestyle.

A surge in disposable income; increase in awareness about sleep disorders; stressful work issues; enhanced intake of caffeine, tobacco, and alcohol; and technological advancements are expected to boost the sleep aids market growth.

However, adverse effects of sleep aids medication in patient with sleep disorders, such as dizziness, diarrhea, constipation, daytime drowsiness; and expiration on sleep drugs patents are expected to hamper the market growth.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:May 8, 2017
Words:290
Previous Article:Immunocore and GSK's collaboration bears fruit.
Next Article:Seattle Genetics to Terminate Sacituzumab Govitecan License Agreement with Immunomedics; Will Settle Shareholder Suit.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters